CLINICAL_TRIALS
trial_result
· 2019-10-22
Clinical Trial Update: Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma [Phase 2]
Summary
Phase 2 pilot trial of hu14.18-IL2 in resectable recurrent stage III or stage IV melanoma has been completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Wisconsin, Madison | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2019-10-22